Recent Finacing
Recent Raise
Sillajen is a Seoul-based oncolytic immunotherapy company developing Pexa-Vec (JX-594), an intravenously delivered oncolytic virus that targets tumors and induces cancer-specific antibodies, currently in Phase III multinational trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor